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AbSTRACT
background: Drug-eluting stents (DES) have changed con-
temporary interventional cardiology practice, enabling 
the approach of increasingly more complex clinical and 
angiographic scenarios. The objective of this study was to 
demonstrate the changes observed in the last 10 years in 
the indication and practice of percutaneous coronary in-
tervention (PCI) at a tertiary private hospital in the State of 
São Paulo. Methods: DESIRE is a single-center prospective 
registry aiming at following the acute and late outcomes of 
consecutive patients treated by DES. Results: From 2002 to 
2011, 4,299 patients were included, with mean age of 64.3 
± 11.2 years, 23% were female and 30.5 were diabetic. The 
total number of lesions treated was 6,518 of which 61.5% 
were type B2/C. During the course of the study, DES were 
progressively more used, reaching a penetration of 88.4% in 
2011. The complexity of PCIs has increased and in the past 
year 1.76 lesions per patient were treated with an average 
of 1.89 DES. The SYNTAX score increased from 12.3 ± 4.4 
(2002-2006) to 15.7 ± 4.7 (2007-2011). Clinical follow-up 
was obtained in 98.2% of the patients, with a median of 5.2 
years, and during this period target-lesion revascularization 
rate was 5%, myocardial infarction was 6.7% and cardio-
vascular death was 4.1%. Stent thrombosis was observed in 
2.4% of the cases. Conclusions: Our results showed a marked 
increment in the complexity profile of patients treated in the 
last 10 years and at the same time confirm the long-term 
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RESUMO
Impacto do Uso Rotineiro de Stents Farmacológicos  
na Prática Intervencionista Contemporânea de  
um Centro Terciário: Experiência de uma  
Década do Registro DESIRE
Introdução: Os stents farmacológicos (SFs) modificaram a 
prática intervencionista contemporânea, permitindo abordar 
cenários clínicos e angiográficos progressivamente mais 
complexos. O objetivo deste estudo foi demonstrar as modi-
ficações ocorridas nos últimos 10 anos na forma de indicar 
e de realizar a intervenção coronária percutânea (ICP) em 
um hospital privado, terciário, do Estado de São Paulo. 
Métodos: O DESIRE é um registro unicêntrico, prospectivo, 
com o objetivo de acompanhar os desfechos agudos e tardios 
de pacientes consecutivos tratados com SFs. Resultados: No 
período de 2002 a 2011, foram incluídos 4.229 pacientes, 
com média de idade de 64,3 ± 11,2 anos; 23% eram do sexo 
feminino, e 30,5%, diabéticos. Foram tratadas 6.518 lesões, 
das quais 61,5% eram do tipo B2/C. Os SFs foram utilizados 
em proporção crescente, alcançando penetração de 88,4% em 
2011. A complexidade das ICPs aumentou, sendo tratada no 
último ano 1,76 lesão por paciente, com média de 1,89 SF. 
O escore SYNTAX, no período de 2002-2006, foi de 12,3 ± 
4,4, enquanto entre 2007-2011 elevou-se para 15,7 ± 4,7. 
O seguimento clínico foi obtido em 98,2% dos pacientes, 
com mediana de 5,2 anos, sendo observada, nesse período, 
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effectiveness of DES, despite the clinical and angiographic 
profile of patients.
 
 
 
 
 
DESCRIPTORS: Angioplasty. Drug-eluting stents. Coronary 
disease. Registries.
ten-year period. For this purpose, a team was formed 
consisting of eight medical researchers, a statistician, 
a database manager, and two professionals dedicated 
to the follow-up of all patients included in the study, 
which was conducted through a standard questionnaire 
administered by telephone, e-mail, and mail.
The present study shows the impact of DES on 
the different types of revascularization (surgical vs. 
percutaneous), as well as the impact of new techno-
logy on the performance of percutaneous interven-
tions, with data that reflects the complexity of these 
procedures, such as the number of treated lesions 
and the number of DES implanted per patient over 
the last decade.
Results
Since 1999, PCI has become the predominantly 
used method of myocardial revascularization at this 
institution (Figure 1). Such predominance has become 
more pronounced since 2002, when DES were intro-
duced, and particularly after 2008, when these devices 
became broadly reimbursed by most private health 
insurers in Brazil.
Since the formation of the DESIRE registry, 4,229 
patients were treated exclusively with DES and included 
in the study. The clinical and angiographic characte-
ristics of this population are shown in Tables 1 and 
2. The mean age of the enrolled subjects was 64.3 ± 
11.2 years; 23% were females; 30.5% were diabetic, 
and approximately 25% of the patients had previously 
undergone a myocardial revascularization procedure 
(either percutaneous or surgical). Note the large number 
of individuals with previous renal dysfunction (9.2%) 
and acute coronary syndrome at the initial clinical 
presentation (40.8%).
From the angiographic viewpoint, a predominance 
of complex lesions was observed (61.5% of type B2/C 
lesions according to American Heart Association/Ameri-
can College of Cardiology classifications), with 5.5% of 
the target lesions localized in bypass grafts and 4.9% 
in ostial locations.
T he advent of drug-eluting stents (DES) modified contemporary interventional practice, allowing a routine and effective approach in traditionally 
unfavorable clinical and angiographic scenarios through 
percutaneous coronary intervention (PCI), for instance, 
lesions in the left main coronary artery.1
However, the relatively high cost of this new 
technology, particularly when compared to the cost of 
bare-metal stents (BMS), the previous primary interven-
tion, made their incorporation into the routines of most 
private hospitals in Brazil a slow process, despite the 
striking benefits of DES, especially in reducing the need 
for new interventions in the target vessel.2-4 To date, 
this technology, which has now celebrated ten years 
of approval for clinical use in Brazil, has not yet been 
authorized by the public health system.
The present study aimed to demonstrate the modi-
fications that have occurred over the past ten years 
regarding the indication and performance of myocardial 
revascularization procedures in patients with coronary 
artery disease in a private tertiary hospital in the state 
of São Paulo.
Methods
Beginning in May 2002, when the first DES was 
approved in Brazil, Drug-Eluting Stents in the Real 
World (DESIRE), a single-center prospective registry, 
was started at Hospital do Coração da Associação do 
Sanatório Sírio (HCor, São Paulo, SP, Brazil) in order 
to monitor acute outcomes (particularly late outcomes) 
in consecutive patients who were treated with DES. 
This registry has no exclusion criteria and evaluated 
all patients treated with at least one DES since 2002, 
thus representing a true picture of the interventional 
practice at this institution.
During this time, following the world trend, several 
changes occurred regarding the indications for PCI, which 
has become the most widespread and comprehensive 
treatment choice for coronary artery disease. The DESIRE 
registry has captured these changes and their impact 
on revascularization treatment outcomes throughout a 
revascularização da lesão-alvo em 5%, infarto do miocárdio 
em 6,7% e óbito cardiovascular em 4,1% dos pacientes. A 
trombose do stent ocorreu em 2,4% dos casos. Conclusões: 
Nossos resultados demonstram marcante incremento no perfil 
de complexidade dos pacientes tratados nos últimos 10 anos 
e, ao mesmo tempo, confirmam a efetividade a longo prazo 
dos SFs, a despeito dos perfis clínico e angiográfico tratados.
DESCRITORES: Angioplastia. Stents farmacológicos. Doença 
das coronárias. Sistema de registros.
Costa Jr. et al. 
One-decade experience of the DESIRE registry
Rev Bras Cardiol Invasiva. 
2012;20(4):355-60
357
Figure 1 – Types of revascularization procedures performed at Hospital 
do Coração da Associação do Sanatório Sírio for the past 13 years. Note 
that, since 1999, PCI has become the predominant revascularization 
method, a position that was consolidated with the 2002 introduction 
of DES. PCI, percutaneous coronary intervention; CABG, coronary 
artery bypass grafting.
Table 1 
basal Clinical Characteristics
Variable n = 4,229
Age, years 64.3 ± 1 1 , 2
Female gender, n (%) 9/2 (23)
Diabetes mellitus, n (%) 1,290 (30.5)
Arterial hypertension, n (%) 3,240 (76.6)
Dyslipidemia, n (%) 2,654 (72.8)
Current smoking, n (%) 1,285 (30.4)
Previous MI, n (%) 959 (22.7)
Previous PCI, n (%) 1,038 (24.5)
Previous CABG, n (%) 1,070 (25.3)
Family history of CAD, n (%) 1,524(36)
Obesity, n (%) 1,137 (27.5)
Renal failure, n (%) 388 (9.2)
Symptoms (clinical presentation), n (%)
Silent ischemia 1,536 (36.3)
Stable angina 968 (22.9)
ACSWSTE 1,580 (37.4)
ACSWNSTE 145 (3.4)
Logistic EuroSCORE, mean ± SD 4.3 ± 5.4 
(0.14-70.2)
MI, myocardial infarction; PCI, percutaneous coronary 
intervention; CABG, coronary artery bypass graft; CAD, 
coronary artery disease; ACSWSTE, acute coronary syndrome 
with ST-segment elevation; ACSWNSTE, acute coronary 
syndrome with no ST-segment elevation.
Table 2 
Pre-procedural angiographic characteristics
Variable
4,229 patients 
(6,518 lesions)
Treated locations, %
1 72.1
2 24.9
3 2.9
Treated vessel
Native coronary, % 94.5
 – ADA 41.7
 – Cx 29.3
 – RCA 27.5
 – LMCA 1.5
Graft, % 5.5
 – Venous 94.1
 – Arterial 5.9
Age of graft, years 11.2 ± 5.5
Lesion classification (ACC/AHA), %
A 6.7
B1 31.8
B2 27.4
C 34.1
Thrombus, % 3
Moderate/severe calcification, % 24.9
Ostial lesion, % 4.9
Bifurcation, % 8.1
Restenosis, % 3.8
Left ventricular function, %
Preserved/mild dysfunction, % ≥ 40
Moderate/severe dysfunction, % < 40
SYNTAX score, mean ± SD 14 ± 4.5
ADA, anterior descending artery; Cx, circumflex artery; 
RCA, right coronary artery; LMCA, left main coronary artery; 
AHA/ACC, American Heart Association/American College of 
Cardiology.
Figure 2 shows the penetration of DES in this 
department throughout the decade. Since the first year 
of its approval for clinical use, these new devices 
have become prevalent in the performance of PCIs, 
particularly since 2007, when these devices started to 
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represent at least 70% percutaneous revascularizations, 
reaching close to 90% in 2011.
Figure 3 indirectly shows the evolution of the 
complexity of percutaneous procedures from 2002 to 
2011. In 2002, a mean of 1.25 lesion per patient was 
treated, using 1.37 DES per PCI, but at the end of the 
decade, this service was treating 1.76 lesion per patient, 
using approximately two DES per intervention (1.89 
DES/patient). This impact on the complexity profiles of 
this patient group may also be observed by assessing 
the SYNTAX angiographic risk scores calculated for 
all patients (from the DESIRE registry) with multives-
sel disease not previously operated upon. Overall, 
the mean SYNTAX in this population was 14 ± 4.5. 
However, if the risk score is divided by the period, it 
can be observed that during the first five years of the 
registry (2002-2006), the mean value was 12.3 ± 4.4, 
while in the last five years (2007-2011), it increased 
to 15.7 ± 4.7.
An important effect of the implementation of DES 
in this clinical routine was the low rate of stenosis 
recurrence in the treated patients (i.e., the marked 
suppression of clinical restenosis). Among the 4,229 
patients included in the study, complete clinical follow-
ups were obtained in most cases (98.2% with a median 
follow-up of 5.2 years). In 5% of cases, there was a 
need for further intervention in the target lesions, most 
of which (91%) were resolved with the implantation of 
another DES. The occurrence of other adverse cardio-
vascular events was low, particularly when considering 
the clinical and angiographic profiles of the assessed 
group (cardiovascular death, 4.1%; myocardial infarction, 
6.7%; stent thrombosis, 2.4%) and the follow-up time. 
discussion
Until the advent of DES, restenosis was the main 
limitation of PCI, occurring in up to 30% of cases after 
using BMS and in 50% of cases treated with balloon 
catheter only.5,6
Early DES studies showed a remarkable reduction in the 
healing response after implanting these stents, with virtual 
abolition of restenosis in lower-complexity scenarios.7,8
Considering the excellent results of these initial 
studies, the applicability of these new devices was 
quickly extended to more complex scenarios in which 
PCI had not yet shown excellent results (e.g., diabetics, 
smaller vessels, restenosis, etc.) or was practiced only 
as an exception (e.g., left main coronary artery).9-12 
However, this rapid growth in the indication of PCI and 
the use of these new devices did not occur homogeneously 
across all continents and countries. The high initial cost 
of these new stents represented the first barrier to their 
unrestricted incorporation into daily practice, particularly 
in countries with more constrained budgets than Brazil.
The second barrier to the broader use of these 
devices was related to the safety of these new tools, 
especially the very late types. At the end of 2006 and 
early 2007, several series of patients exhibited a relatively 
new phenomenon: thrombosis after the first month of 
PCI (late) and sometimes after the first year (very late), 
which raised the suspicion that these devices could result 
in higher rates of late mortality.13-20
Figure 2 – Dissemination of DES in interventional practice at the 
Hospital do Coração da Associação do Sanatório Sírio. Note that 
since being approved for clinical use in 2002, these new devices have 
become the preferred treatment choice at this institution, represent-
ing 88.4% of the stents used in 2011. BMS are restricted to patients 
with contraindications for the formal dual antiplatelet therapy or with 
surgical procedures planned within one year of the intervention. DES, 
drug-eluting stents; BMS, bare-metal stents.
Figure 3 – Annual increment in the number of treated lesions and 
stents implanted according to the DESIRE registry. Within a decade, 
there was an increase of 40.8% in the number of treated lesions and 
a 36.5% increase in the rate of stents implanted per patient.
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As seen in Figures 1 and 2, the adverse global 
scenarios had some effect in this service’s practice as 
well. Between 2006 and 2007, there was a reduction 
of almost 20% in the PCI indication in HCor at the 
expense of surgical revascularization procedures (Fig. 
1). However, among the patients treated with PCI, the 
DES maintained their hegemony as the primary tool 
for revascularization, with a modest reduction in their 
use of 2.1% compared to the previous year (79.6% in 
2006 vs. 77.5% in 2007) (Figure 2).
However, this negative impact, at least in this ser-
vice’s experience, was short-lived. From 2008 onward, a 
gradual increase in PCI indication and DES use in this 
service was observed, resulting in the performance of 75% 
of revascularizations through a catheter and the use of 
DES in nearly 90% of cases at this institution in 2011.
Although a definitive explanation for these observa-
tions cannot be established, it is possible to speculate on 
the role of the DESIRE registry in this scenario. During 
the study decade, data from DESIRE resulted in more 
than 180 studies, which were presented at national and 
international events and over 30 publications in national 
and international journals.21 The broad dissemination of 
this institution’s experience, with a low rate of adverse 
events even after a long follow-up, appears to have 
had an important role in the confirmation of the good 
results for this revolutionary technology.
In parallel, the results of several meta-analyses 
comparing DES and BMS that demonstrated the greater 
efficacy of the new devices (e.g., the safety was at 
least comparable to that of BMS) were published in-
ternationally.22-25
Moreover, new generations of DES appeared with 
structural characteristics that improved safety (e.g., 
decreased amounts of antiproliferative drugs, more 
biocompatible and/or biodegradable polymers, etc.), 
and without compromising the excellent effectiveness 
achieved by the first generation.26-28 The advent of these 
new stent generations, in addition to providing improved 
safety profiles, also stimulated competition in the DES 
market, which had been previously restricted to only 
two manufacturers. This expansion, together with the 
increased number of stents used, contributed to lower 
prices and facilitated DES use.
However, studies have shown that despite the price 
reduction observed in the last decade, Brazil still has the 
highest cost DES among the major consumer markets 
worldwide, which represents a paradox considering the 
economic environment of this country.
With the imminent implementation of these devices 
for use in patients treated by Unified Health System 
(Sistema Único de Saúde – SUS), it is expected that 
the last barrier (cost) will finally be removed and that 
it will be possible to provide more universal access to 
this remarkable technology.
study limitations
There are two main limitations related to this 
study: 1) the lack of detailed follow-up of the patients 
undergoing PCI in this hospital before 2002, when 
DESIRE began, and 2) the absence of a control group 
consisting of patients treated with BMS. The latter limi-
tation is attributed to the fact that, from the beginning, 
the use of DES was defined as a standard procedure, 
which was not used only in the patients with a clear 
contraindication to prolonged dual antiplatelet therapy 
or in cases in which the health insurer did not authorize 
the use of these devices. Therefore, a control group 
would have been the result of an important selection 
bias, with limited applicability for comparisons between 
the instruments.
conclusions
According to the results of the present study, there 
was a significant increase in the complexity profiles of the 
patients treated in the last ten years and a confirmation 
of the long-term effectiveness of DES, notwithstanding 
the clinical and angiographic profiles.
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